CStone Pharmaceuticals Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
147
- Stock Symbol
-
02616
- Share Price
-
$0.70
- (As of Thursday Closing)
CStone Pharmaceuticals General Information
Description
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
Contact Information
Website
www.cstonepharma.comCorporate Office
- C1, BioNano Park
- Number 218 Xinghu Street
- Suzhou, Jiangsu 215123
- China
Corporate Office
- C1, BioNano Park
- Number 218 Xinghu Street
- Suzhou, Jiangsu 215123
- China
CStone Pharmaceuticals Timeline
CStone Pharmaceuticals Stock Performance
As of 12-Nov-2026, CStone Pharmaceuticals’s stock price is $0.70. Its current market cap is $1.11B with 1.59B shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.70 | $0.70 | $0.51 - $1.33 | $1.11B | 1.59B | 9.3M | -$0.04 |
CStone Pharmaceuticals Financials Summary
As of 30-Jun-2026, CStone Pharmaceuticals has a trailing 12-month revenue of $60.8M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 876,702 | 962,161 | 311,507 | 264,220 |
| Revenue | 60,770 | 37,487 | 56,750 | 65,562 |
| EBITDA | (53,510) | (52,434) | (5,422) | (45,529) |
| Net Income | (59,895) | (60,768) | (12,711) | (51,907) |
| Total Assets | 302,606 | 194,144 | 190,883 | 234,461 |
| Total Debt | 52,579 | 49,812 | 48,763 | 51,272 |
CStone Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CStone Pharmaceuticals Comparisons
Industry
Financing
Details
CStone Pharmaceuticals Competitors (12)
One of CStone Pharmaceuticals’s 12 competitors is Alphamab Oncology, a Formerly VC-backed company based in Suzhou, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alphamab Oncology | Formerly VC-backed | Suzhou, China | ||||
| Abbisko Medicine | Formerly VC-backed | Shanghai, China | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China | ||||
| Brii Biosciences | Formerly VC-backed | Beijing, China | ||||
| Taibang Biological Group | Private Equity-Backed | Beijing, China |
CStone Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CStone Pharmaceuticals Patents
CStone Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026200788-A1 | Bispecific antibodies and uses thereof | Pending | 24-Mar-2025 | ||
| WO-2026098633-A1 | Conjugates and uses thereof | Pending | 08-Nov-2024 | ||
| WO-2026067794-A1 | Trispecific antibodies and uses thereof | Pending | 30-Sep-2024 | ||
| WO-2025242212-A1 | Anti-sstr2 antibodies | Pending | 24-May-2024 | ||
| EP-4754138-A1 | Antibodies against ror1 and uses thereof | Pending | 28-Jul-2023 | C07K16/2803 |
CStone Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CStone Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CStone Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.95 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
CStone Pharmaceuticals FAQs
-
When was CStone Pharmaceuticals founded?
CStone Pharmaceuticals was founded in 2015.
-
Where is CStone Pharmaceuticals headquartered?
CStone Pharmaceuticals is headquartered in Suzhou, China.
-
What is the size of CStone Pharmaceuticals?
CStone Pharmaceuticals has 147 total employees.
-
What industry is CStone Pharmaceuticals in?
CStone Pharmaceuticals’s primary industry is Drug Discovery.
-
Is CStone Pharmaceuticals a private or public company?
CStone Pharmaceuticals is a Public company.
-
What is CStone Pharmaceuticals’s stock symbol?
The ticker symbol for CStone Pharmaceuticals is 02616.
-
What is the current stock price of CStone Pharmaceuticals?
As of 12-Nov-2026 the stock price of CStone Pharmaceuticals is $0.70.
-
What is the current market cap of CStone Pharmaceuticals?
The current market capitalization of CStone Pharmaceuticals is $1.11B.
-
What is CStone Pharmaceuticals’s current revenue?
The trailing twelve month revenue for CStone Pharmaceuticals is $60.8M.
-
Who are CStone Pharmaceuticals’s competitors?
Alphamab Oncology, Abbisko Medicine, BeOne Medicines, Brii Biosciences, and Taibang Biological Group are some of the 12 competitors of CStone Pharmaceuticals.
-
What is CStone Pharmaceuticals’s annual earnings per share (EPS)?
CStone Pharmaceuticals’s EPS for 12 months was -$0.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
